The approval of the HCC indication was based on data from the Phase 3 CELESTIAL trial (N=707) which randomized patients who previously received sorafenib to either Cabometyx or placebo.
The approval of the HCC indication was based on data from the Phase 3 CELESTIAL trial (N=707) which randomized patients who previously received sorafenib to either Cabometyx or placebo.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![Maak saaie content interessant: spelen met invalshoeken [3 tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/01/high-angle-shot-of-a-diverse-business-team-hands-p-2023-11-27-05-19-55-utc-1-80x60.jpg)